Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, September 20, 2021
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Oncology, Investor, Cytokine, Conference, NASDAQ, Cancer, Company, Webcast, Technology, Protein, Degenerative disease, Vaccine
Geotags: 
United States, California
⚠ generated by AI ↴
Organisation: 
XENCOR, INC.
Summary
Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m.
  • A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. ET / 1:00 p.m. PT.

A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Copyright: 
Copyright Business Wire 2021